ThermoGenesis Holdings is engaged in the development and commercialization of automated cell processing technologies for the cell and gene therapy field. Co. markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform. Co. provides the AutoXpress® and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress platform under development for bio-manufacturing for immuno-oncology applications. Co. has two business segments: Device Segment and Clinical Development Segment. The THMO stock yearly return is shown above.
The yearly return on the THMO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the THMO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|